Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.32 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090015 | 0.93 | CARM1 (0.37) | MAPK8MAPTDHODH | |
| SCHEMBL10089970 | 0.93 | GPR6 (0.36) | MAPK8LIPGEPHX2CACNA1GCACNA1H | |
| SCHEMBL10089937 | 0.93 | HSD17B13 (0.40) | MAPK8EPHX2HSD17B13MAPK1RIPK1 | |
| SCHEMBL10089841 | 0.92 | TP53 (0.38) | MAPK8TP53MAPT | |
| SCHEMBL10089844 | 0.92 | MAPK8 (0.35) | MAPK8LIPGEPHX2HSD17B13TP53 | |
| SCHEMBL10089948 | 0.91 | TP53 (0.35) | MAPK8CACNA1GCACNA1HTP53DHODH | |
| SCHEMBL10089883 | 0.90 | P2RX7 (0.36) | EPHX2HSD17B13TP53MAPK1 | |
| SCHEMBL10089873 | 0.90 | MAPK8 (0.36) | MAPK8TP53 | |
| SCHEMBL10089978 | 0.90 | PPARG (0.36) | MAPTDHODH | |
| SCHEMBL10089974 | 0.90 | HSD17B13 (0.34) | MAPK8LIPGEPHX2HSD17B13TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791143-B2 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | MAPK8 4028/4885LIPG 4719/4885EPHX2 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.